BioMarin Pharmaceutical (BMRN) concentration risks

The company's concentration profile spans customer, supply, and manufacturing dependencies, several of which carry a high share by disclosed size. On the customer side, one named party is the company's sole customer for one of its products and is responsible for all downstream distribution, marketing, and sales of that product — a high-share dependency where commercial control of that revenue stream sits entirely outside the company. Separately, three customers in aggregate generated 37% of net product revenue in 2025, a moderate customer-base concentration that is meaningful though not dominant. Supply and manufacturing dependencies compound the customer-side risks. Certain raw materials are available in some instances from a single recognized supply source, and for certain manufacturing steps there is only one approved contract manufacturer — both high-share dependency exposures where a disruption would have no immediate substitute. These constraints are typical for rare-disease biologics but make the supply chain structurally fragile at multiple points. VOXZOGO is identified as a key product contributor within the portfolio, representing a moderate product-concentration by disclosed size. Because the filing presents its revenue figure in a pipe-delimited format, that number is treated qualitatively here. On balance, the disclosed profile shows a business where customer, supply, and manufacturing dependencies converge. The sole-distribution arrangement and the sole-source supply and manufacturing exposures are the most acute, as each represents a single point of failure; the customer and product diversification that exists is moderate rather than deep.

For the engine’s reasoning on BMRN’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.